NASDAQ:BCRX

BioCryst Pharmaceuticals Stock Forecast, Price & News

$15.89
-0.47 (-2.87 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.70
$16.35
50-Day Range
$9.50
$17.24
52-Week Range
$3.30
$17.74
Volume4.69 million shs
Average Volume5.62 million shs
Market Capitalization$2.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.65
30 days | 90 days | 365 days | Advanced Chart
Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


BioCryst Pharmaceuticals logo

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

883rd out of 2,097 stocks

Biological Products, Except Diagnostic Industry

129th out of 198 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

Is BioCryst Pharmaceuticals a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioCryst Pharmaceuticals stock.
View analyst ratings for BioCryst Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than BioCryst Pharmaceuticals?

Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioCryst Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioCryst Pharmaceuticals
.

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.10. The biotechnology company had revenue of $19.06 million for the quarter, compared to analysts' expectations of $12.80 million. BioCryst Pharmaceuticals had a negative net margin of 653.70% and a negative trailing twelve-month return on equity of 5,272.40%.
View BioCryst Pharmaceuticals' earnings history
.

How has BioCryst Pharmaceuticals' stock been impacted by Coronavirus?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BCRX shares have increased by 513.5% and is now trading at $15.89.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BCRX?

10 brokerages have issued 12-month price objectives for BioCryst Pharmaceuticals' stock. Their forecasts range from $6.00 to $21.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $15.44 in the next year. This suggests that the stock has a possible downside of 2.8%.
View analysts' price targets for BioCryst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Mr. Jon P. Stonehouse, CEO, Pres & Exec. Director (Age 60, Pay $1.12M)
  • Mr. Anthony J. Doyle, Sr. VP & CFO
  • Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 66, Pay $786.97k)
  • Dr. Yarlagadda S. Babu, Chief Discovery Officer (Age 68, Pay $682.62k)
  • Ms. Megan T. Sniecinski, Sr. VP & Chief Bus. Officer (Age 40, Pay $740.95k)
  • Dr. Helen M. Thackray, Chief R&D Officer (Age 53, Pay $55k)
  • Mr. Michael L. Jones, Exec. Director of Fin. & Principal Accounting Officer (Age 51)
  • Mr. John D. Bluth, Sr. VP of Investor Relations & Corp. Communications (Age 48)
  • Ms. Alane P. Barnes, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 55)
  • Mr. Robert C. Stoner, VP of HR

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.14%), Baker BROS. Advisors LP (7.15%), Sarissa Capital Management LP (4.30%), Artisan Partners Limited Partnership (1.70%), Geode Capital Management LLC (1.68%) and Deerfield Management Company L.P. Series C (1.47%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski and William P Sheridan.
View institutional ownership trends for BioCryst Pharmaceuticals
.

Which institutional investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Renaissance Technologies LLC, Oracle Investment Management Inc., Sarissa Capital Management LP, Cubist Systematic Strategies LLC, Ghost Tree Capital LLC, UBS Group AG, and DG Capital Management LLC. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Alane P Barnes, George B Abercrombie, and William P Sheridan.
View insider buying and selling activity for BioCryst Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying BioCryst Pharmaceuticals stock?

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Goldman Sachs Group Inc., Nuveen Asset Management LLC, Lisanti Capital Growth LLC, Integral Health Asset Management LLC, Geode Capital Management LLC, Citigroup Inc., and Gilder Gagnon Howe & Co. LLC. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, and Megan Sniecinski.
View insider buying and selling activity for BioCryst Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $15.89.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals has a market capitalization of $2.82 billion and generates $17.81 million in revenue each year. The biotechnology company earns $-182,810,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals employs 246 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is www.biocryst.com.

Where are BioCryst Pharmaceuticals' headquarters?

BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.